{
    "drug_name_en": "empagliflozin",
    "side_effects": {
        "Cardiovascular": {
            "Postmarketing reports": [
                [
                    "hypotension"
                ]
            ]
        },
        "Dermatologic": {
            "Common": [
                [
                    "pruritus",
                    "rash"
                ]
            ],
            "Postmarketing reports": [
                [
                    "skin reactions includingangioedemaandurticaria"
                ]
            ]
        },
        "Gastrointestinal": {
            "Common": [
                [
                    "nausea"
                ]
            ],
            "Postmarketing reports": [
                [
                    "constipation"
                ]
            ]
        },
        "Genitourinary": {
            "Very common": [
                [
                    "female urinary tract infections (up to 18.4%)"
                ]
            ],
            "Common": [
                [
                    "female genital mycotic infections",
                    "increased urination",
                    "male urinary tract infections"
                ]
            ],
            "Uncommon": [
                [
                    "phimosis",
                    "male genital mycotic infections",
                    "nocturia",
                    "dysuria"
                ]
            ],
            "Postmarketing reports": [
                [
                    "urosepsis",
                    "pyelonephritis",
                    "necrotizing fasciitis of the perineum (fournier's gangrene)"
                ]
            ]
        },
        "Hematologic": {
            "Common": [
                [
                    "increased hematocrit"
                ]
            ]
        },
        "Hepatic": {
            "Frequency not reported": [
                [
                    "hepatic injury"
                ]
            ]
        },
        "Hypersensitivity": {
            "Postmarketing reports": [
                [
                    "angioedema",
                    "hypersensitivity reactions"
                ]
            ]
        },
        "Metabolic": {
            "Very common": [
                [
                    "hypoglycemia",
                    "especially in combination with other glucose lowering therapies (up to 41.3%)",
                    "adverse reactions related to volume depletion (up to 11.4%)"
                ]
            ],
            "Common": [
                [
                    "increased low-density lipoprotein cholesterol",
                    "dyslipidemia"
                ]
            ],
            "Postmarketing reports": [
                [
                    "ketoacidosis"
                ]
            ]
        },
        "Musculoskeletal": {
            "Common": [
                [
                    "arthralgia"
                ]
            ]
        },
        "Other": {
            "Common": [
                [
                    "thirst"
                ]
            ],
            "Frequency not reported": [
                [
                    "lower limb amputation"
                ]
            ]
        },
        "Renal": {
            "Very rare": [
                [
                    "tubulo-interstitial nephritis"
                ]
            ],
            "Frequency not reported": [
                [
                    "increased serum creatinine",
                    "decreased estimated gfr"
                ]
            ],
            "Postmarketing reports": [
                [
                    "acute kidney injury",
                    "urosepsis",
                    "pyelonephritis"
                ]
            ]
        },
        "Respiratory": {
            "Common": [
                [
                    "upper respiratory tract infection"
                ]
            ]
        }
    }
}